CA215 (0.1 Au/ml)   Lung (n) Liver (n) Ovary (n) Esophagus (n) Breast (n) Stomach (n)
CEA (5 ng/ml) I 52% (112) 74% (58) - 61%(23) 71% (44) 60% (30)
II 64% (33) 54% (35) - 47% (19) 95% (20) 50% (14)
III 97% 81% - 65% 96% 70%
AFP (20 ng/ml) I - 74% (58) - - - -
II - 50% (40) - - - -
III - 85% - - - -
CA125 (35 Au/ml) I 52% (112) 74% (58) 59% (68) 61% (23) - -
II 85% (13) 85% (13) 59% (66) 50% (12) - -
III 85% 92% 82% 75% - -
CA19-9 (37 AU/ml) I - 74% (58) - - - 60% (30)
II - 55% (22) - - - 75% (16)
III - 82% - - - 81%
CA15-3 (30 AU/ml) I - - - - 71% (44) -
II - - - - 83% (6) -
III - - - - 83% -
β2 microglobulin (2.6 ng/ml) I - 74% (58) 59% (68) - - -
II - 56% (16) 90% (10) - - -
III - 81% 100% - - -
Cyfra 21-1 (3.3 ng/ml) I 52% (112) - - - - -
II 50% (52) - - - - -
III 77% - - - - -
Table 1: Comparative positive detection rates of various cancers by CA215-based and other cancer-associated antigen-based enzyme immunoassay kits. I: CA215 only; II: other marker only; III: combined.